Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Hydra Biosciences, Cubist Form Collaboration
Hydra Biosciences has entered into an agreement with Cubist Pharmaceuticals for a joint collaboration to develop novel ion channel drugs. The deal focuses on Hydra’s research and development
Hydra Biosciences has entered into an agreement with Cubist Pharmaceuticals for a joint collaboration to develop novel ion channel drugs. The deal focuses on Hydra’s research and development
AVX Corporation (AVX) and Cabot have announced the resolution of all outstanding litigation between the parties relating to the supply of tantalum by Cabot to AVX. The terms
SIRO Clinpharm, a contract research organisation (CRO) with its base in India, US, Europe and Israel has announced expansion of its Clinical Trials Supplies facility in Mumbai, India.
Abbott has introduced ZonePerfect Indulgence Nutrition Squares, a new snack with a soft, whipped center. ZonePerfect Indulgence squares are available in three flavors: Chocolate Peanut Butter Mousse, Caramel
Icagen and Pfizer have jointly presented the data related to their collaboration focused on certain sodium channels for the treatment of pain and related conditions at the Neuroscience
LDN Research Trust has said that the lives of 100,000 multiple sclerosis (MS) sufferers in the UK could be greatly improved while saving the National Health Service (NHS)
According to the findings of European Sexual Confidence Survey, 87% of adults believe that good sex is linked to a man’s ability to achieve and sustain a firm
Takeda Pharmaceutical (Takeda) has received approval from the Japanese Ministry of Health, Labour and Welfare for an additional indication of Basen Tablets 0.2 and Basen OD Tablets 0.2
Novartis has received a Complete Response letter from the FDA as part of the US regulatory review for QAB149 (indacaterol). It is an investigational once-daily bronchodilator for the
Biogen Idec and Biovitrum are planning to advance their long-acting, fully-recombinant Factor IX Fc fusion protein (rFIXFc) into a registrational clinical trial in hemophilia B patients. Reportedly, the